Duct carcinoma in situ (DCIS) of the breast comprises about 20% of new breast malignancies in mammographically screened populations. Treatment consists of breast conserving surgery (BCS) in about 75% of women, usually followed by post-operative radiotherapy (RT). This halves the risk of ipsilateral new cancer events, with a further 1/3rd reduction through the use of oral endocrine therapy (OET). Additionally, OET reduces risk of new breast cancer by one-half. However, OET is declined by more than half of DCIS patients, given its thromboembolic and uterine risks (selective estrogen receptor modulators), and musculoskeletal effects (aromatase inhibitors). Given the benefits of OET for DCIS patients, drug delivery methods that avoid the adverse effects of these agents will represent a significant advance. Transdermal delivery is well-recognized as an effective alternative to oral delivery. Advantages include low systemic exposure, longer retention in the local tissue, delayed excretion, and avoidance of first-pass hepatic metabolism. Further, the transdermal delivery of active metabolites obviates the potential role of genetic variation in drug metabolism as a barrier to effective therapy. Encouraging preliminary data on local transdermal therapy (LTT) with 4-hydroxytamoxifen (4-OHT) applied to the breast skin have led us to conduct clinical trials aimed at establishing the equivalence of 4-OHT/LTT and OET. If successful, this will be a novel and potentially transformative development for the DCIS population, and for women at high risk for breast cancer. However, there are significant knowledge gaps regarding the determinants of individual variations in dermal permeation and the dynamics of drug retention in the breast. Furthermore, current studies exclude women who have undergone breast RT because this may alter dermal permeation and/or distribution through the breast. Since DCIS patients who receive RT to the affected breast derive additional protection for both breasts through the use of OET, an evaluation of the effect of RT on drug permeation through radiated skin is important. The major barrier to dermal permeation is the stratum corneum, but recent preclinical data implicate Group A: core biopsy both breasts Current age (years) Interval since unilateral RT (years) &lt;1 2-5 40-70 N=45 N=45 Group B: An additional 10-15 subjects will be recruited from women with prior RT in the past 5 years, now undergoing mastectomy xenobiotic transporters in transdermal delivery. Additionally, radiation effects on skin and the breast tissue evolve over time, with possible disturbance of the vascular-lymphatic circulation of the breast that may interfere with drug dissemination. Thus it is clearly important to evaluate both the determinants and dynamics of LTT, in the normal skin and breast, as well of the effects of breast RT on its feasibility. We are proposing a clinical trial, to address two main questions: 1) what are the determinants of inter-individual differences in dermal permeation? 2) How does breast radiotherapy affect permeation? Our design addresses the effect of interval since RT on dermal permeation in the non-radiated (non-RT) and radiated (RT) breast in Group A. We will enroll 90 DCIS patients who received BCS+RT for unilateral DCIS, and have an intact contralateral healthy breast, are not on oral tamoxifen, and agree to apply 4-OHT gel to both breast for three weeks. This will be followed by core needle biopsies (CNB) of both breasts plus a 5 mm skin punch biopsy. In Group B (N=12) the design is similar, but more
|Effective start/end date||2/5/19 → 1/31/24|
- National Cancer Institute (5R01CA235647-05)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.